About this trial
Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia.
Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia.
The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
singleton pregnancies
age ≥ 18 years
patient's ability to provide consent
written informed consent
Disqualifiers
lack of consent
language barrier
severe fetal chromosomal/genetic/structural anomalies known at study enrollment
smoking in the last two hours before measurement
Trial population
women scheduled for a routine ultrasound scan in first or second trimester
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Number of patients with Preeclampsia
Risk ratio of the preeclampsia screening
Secondary outcomes
Number of patients with an adverse maternal event
Number of patients with an adverse perinatal event
Sponsors and contacts
Click on the lead sponsor to view all of their trials.